GlassScriptPhysician profile
Golnar Lashgari
NPI 1376957423
$4,868.39
in general payments reported to CMS, 2019-2025
36 companies · $252 in 2025
The $252 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $923 · 2020: $423 · 2021: $1,025 · 2022: $1,040 · 2023: $647 · 2024: $558 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,457.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,173.61 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $536.43 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $378.51 | 2021-2025 | |
| Amgen INC. | $374.88 | 2019-2025 | Evenity, Otezla, Repatha |
| Astellas Pharma US INC | $305.84 | 2019-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $267.82 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $262.83 | 2019-2024 | Farxiga |
| Pfizer INC. | $171.18 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.62 | 2019-2024 | Jardiance, Synjardy |
| Takeda Pharmaceuticals U.S.A., INC. | $106.24 | 2021-2022 | |
| Lundbeck LLC | $103.62 | 2022-2023 | Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.10 | 2022-2024 | Xifaxan |
| Amarin Pharma, INC. | $84.92 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $83.85 | 2021-2022 | |
| Glaxosmithkline, LLC. | $79.62 | 2019-2024 | Trelegy Ellipta |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $77.53 | 2024-2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $64.97 | 2021-2022 | |
| Abbott Laboratories | $63.48 | 2022-2023 | Freestyle Libre 3 |
| Neos Therapeutics, LP | $49.64 | 2021-2022 | |
| Eisai INC. | $48.25 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $40.86 | 2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $35.97 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $33.98 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.48 | 2023-2024 | |
| Daiichi Sankyo INC. | $31.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $29.91 | 2021 | |
| Exact Sciences Corporation | $25.90 | 2024 | Cologuard Collection Kit |
| Allergan, INC. | $23.53 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $22.64 | 2025 | Voquezna |
| Organon LLC | $21.33 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.60 | 2022 | |
| Axsome Therapeutics, INC. | $19.81 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $16.21 | 2024 | Vaxneuvance, Vaxelis, Gardasil |
| Medtronic, INC. | $13.81 | 2025 | Venaseal |
| Sanofi Pasteur INC. | $13.76 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Golnar Lashgari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.